// App-Quantinova.ai

: Association of Body Weight with Efficacy and Safety of Apixaban and Rivaroxaban in Relation to Low Molecular Heparin and Vitamin K Antagonists in Acute Venous Thromboembolism

Researchers

Presenter

  • W. Wysokinski

Principal Investigators

  • R. McBane

  • D. Froehling

  • D. Vlazny

  • D. Bott-Kitslaar

  • D. Houghton

  • W. Kuczmik

  • K. Sutkowska

  • K. Bator

  • D. Hodge

  • L. Peterson

  • A. Casanegra

Medical Centers

  • Mayo Clinic Rochester, Rochester, Minnesota, United States

  • University Medical School of Wroclaw, Wroclaw, Poland

  • Mayo Clinic, Jacksonville, Jacksonville, Florida, United States

Locations

  • United States

  • Poland

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

  • Blood/haematological Diseases

  • Cardiovascular (CVS)

Disease

  • Venous thrombosis

Biomarkers

  • N/A

Drug/Treatment

  • rivaroxaban

  • apixaban

  • Heparin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved